Welcome

BioStrategics Consulting Ltd provides a range of management-level clinical development consulting services to the pharmaceutical and biotechnology industries, including:

  • Clinical development strategy and management, especially for development-stage companies
  • IND planning and preparation
  • Conceptualization, implementation, and management of Phase 1, Phase 2, first-in-man, and proof-of principle clinical trials
  • FDA and other regulatory authority submissions and meetings
  • Clinical strategic planning for small molecules, biotechnology products, immunotherapeutic agents, novel drug delivery technologies, and medical devices in virtually all therapeutic areas
  • New technology assessment, due diligence, and clinical planning
  • Clinical development advisory services to senior-level management (CEO, COO, CSO, BOD).

Since its founding in 1999, BioStrategics Consulting Ltd has provided clinical research leadership for:

  • More than 25 Investigational New Drug applications, Clinical Trial Applications, or similar regulatory submissions
  • Multiple pre-IND and milestone meetings with FDA
  • Numerous first-in-man clinical trials, both in healthy volunteer and in target patient populations
  • Proof-of-principle clinical trials in oncology, rheumatology, dermatology, ophthalmology, autoimmune disease, infectious disease, immunotherapy, endocrinology/metabolic disease, and hematology
  • Clinical trials programs that align with business success, efficiently achieve value inflection points, and have (in some cases) enabled advantageous exit events
  • Clinical trial operational teams on 4 continents
  • Due diligence, business development, partnership, and corporate strategic analysis projects of preclinical-, clinical-, and commercial-stage projects.

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player


Home   |   Success Stories   |   Services Offered    |   About Us   |   Contact Us

©2013 BioStrategics Consulting Ltd. All rights reserved.    Site designed and developed by 3DMedia Network